Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
554.4 USD | +1.13% | -0.18% | -5.20% |
May. 21 | Declaration of Voting Results by Chemed Corporation | CI |
May. 21 | RBC Cuts Price Target on Chemed to $697 From $712, Maintains Outperform Rating | MT |
Strengths
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 27.1 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.20% | 8.36B | C+ | ||
+25.52% | 88.99B | C+ | ||
-24.52% | 74.82B | B- | ||
-5.56% | 25.03B | C+ | ||
+4.31% | 17.88B | A- | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+79.20% | 13.21B | C+ | ||
+70.11% | 13.08B | C- | ||
+40.44% | 12.9B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHE Stock
- Ratings Chemed Corporation